The tyrosine kinase inhibitor Imatinib Mesylate has dramatically improved the clinical
outcome of chronic myeloid leukemia (CML) patients in the chronic phase of the disease …

Imatinib mesylate is a relatively new drug that targets the BCR-ABL chimeric protein, the
molecular basis of chronic myeloid leukemia (CML). A phase II clinical trial in 39 Japanese …

There are few publications on responses of patients with chronic phase chronic myeloid
leukemia (CP-CML) from the Indian sub continent to imatinib mesylate (IM). This study …

Within the past few years, the introduction of imatinib mesylate (imatinib) has profoundly
changed the management of patients with chronic myelogenous leukemia. This review …

Imatinib mesylate (Gleevec™, Glivec®, formerly STI571; Novartis Pharmaceuticals) is an
inhibitor of the Bcr-abl tyrosine kinase that is central to the pathogenesis of chronic myeloid …

Imatinib has revolutionized the treatment of chronic myeloid leukemia (CML) and there is no
doubt about its role in the first-line therapy of this myeloproliferation. However, there is …

A prospective multicenter Phase II study was performed to examine the efficacy and safety of
imatinib therapy in newly diagnosed Japanese patients with chronic‐phase CML. Patients …

Background Chronic myeloid leukemia (CML) is a malignant disorder of hematopoietic stem
cells. Imatinib mesylate offers clinical benefits during advanced phases of CML, and high …

Background Chronic myeloid leukemia (CML)-study IV was designed to explore whether
treatment with imatinib (IM) at 400mg/day (n= 400) could be optimized by doubling the dose …

Imatinib (imatinib mesylate, Gleevec®[formerly known as STI571], Novartis Pharmaceuticals,
Basel, Switzerland) is a protein tyrosine kinase inhibitor that is approved by the US Food …